CDK9 and cardiac hypertrophy: These seminal findings suggested a role for the CDK9/PTEF-b transcriptional complex in cardiac hypertrophy, although the therapeutic potential of Pol II kinase inhibition could not be assessed due to lack of potent and specific chemical probes that were suitable for in vivo administration.